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January 17, 2006:464–71ent. Enhanced production of EPO could therefore also serve as a
ompensatory mechanism under ischemic conditions and reflect the
everity of ischemic injury.
In the present study, patients with higher EPO levels and
maller infarct size also had lower hemoglobin levels. This is in
ontrast to previous findings, namely that a low hemoglobin
oncentration is associated with higher mortality in patients with
table coronary artery disease (7) and acute MI (8).
In addition, a very weak correlation between enzymatic infarct
ize and endogenous EPO levels should awake cautiousness as to
he interpretation of the presumed effect of endogenous EPO on
educing the infarct size. Moreover, the serum EPO levels were
easured almost 10 hours after the angioplasty and could thus
eflect peri- and postprocedural blood loss, or ischemia-triggered
PO production.
Finally, we believe that the potential mechanism of protective
PO action in these patients might be different from that
uggested by the investigators. In an acute ischemic situation,
escuing the cardiomyocytes from cell death (apoptosis) seems a
ore plausible explanation than increased neovascularization
hrough progenitor cell stimulation. Further studies in larger
ohorts of patients should elucidate the precise role of endogenous
PO in acute coronary syndromes. Moreover, therapy of patients
ith MI with exogenous EPO may be considered in the future.
Erik Lipsic, MD
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e appreciate the interest and thoughtful comments of Dr. Lipsic
nd colleagues regarding our study (1). The conclusions of our
tudy were that a higher endogenous erythropoietin (EPO) level
an predict a smaller infarct size in patients with acute myocardial
nfarction (MI) subjected to successful primary percutaneous
oronary intervention (PCI), and that this might be attributed to
he potentially protective effect of endogenous EPO against
schemia-reperfusion injury in humans. As pointed out by Dr.
ipsic and colleagues, these conclusions may be in contrast to
hose of studies by Dr. Lipsic and colleagues (2) and by others as
ell (3). They reported that a lower hemoglobin content was
ssociated with higher mortality in patients with acute MI (2) and
table coronary artery disease (CAD) (3). We would like to
mphasize, however, that in our study the hemoglobin concentra-
ion was not an independent predictor of the infarct size, whereas
he endogenous EPO level was. We believe that we cannot directly
ompare the results of our study with those of the two studies by
r. Lipsic and colleagues and by others because they did not
easure the serum EPO level in their patients.
Dr. Lipsic and colleagues also reported that, in patients with
hronic heart failure, elevated plasma EPO levels are associated
ith an impaired prognosis (4). The mechanisms of the increased
lasma EPO levels in some patients with chronic heart failure are
till unclear, and they may be different from those in the patients
ith acute MI in our study. As described in our report (1), it is
ossible that current smoking increased the hemoglobin content in
he blood and affected the serum EPO levels of the patients in the
ow EPO group. With regard to the timing of the blood sampling
or the serum EPO level, we collected the blood samples 9.9 
.2 h after the onset of acute MI as described in the Methods
ection of our study. We believe that Dr. Lipsic and colleagues
isunderstood this issue.
We agree with the investigators that a future study with a larger
umber of patients is needed to draw a more definitive conclusion
egarding the role of endogenous EPO in acute MI.
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ntravascular Ultrasound Analysis of
olymer-Based Paclitaxel-Eluting Stents
ith great interest I read the report by Weissman et al. (1) regarding
ntravascular ultrasound (IVUS) analysis of polymer-based
aclitaxel-eluting stents. The investigators stated in the text that
positive remodeling assessed as the absolute increase in the
xternal elastic membrane volume over time tended to be slightly
ore prominent with the TAXUS stent (7.66  48.64 mm3 vs.
12.29  36.05 mm3, respectively, p  0.064).” Also Figure 1
uggested positive remodeling in the TAXUS stent. However,
able 2 of their article (1) shows an inconsistent result, that is,
ecrease of external elastic membrane volume in the TAXUS-stent
roup (283  91 mm3 at postimplantation vs. 280  89 mm3 at
ine-month follow-up). Because a previous IVUS analysis has also
uggested positive remodeling in the TAXUS stent (2), it may be
f great importance to better clarify this result.
Hideaki Kaneda, MD
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apan
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EPLY
e appreciate Dr. Kaneda’s astute observation about the data
ontained in our report (1) on the intravascular ultrasound (IVUS)
esults from TAXUS-IV. It is indeed true that there was a trend for
he vessel receiving a TAXUS stent to demonstrate positive remod-
ling, similar to prior drug-eluting stent (DES) reports. The analysis
or remodeling used only TAXUS and non-TAXUS patients with
omplete volumetric IVUS data of the external elastic membrane
EEM) throughout the stent length at both the time of stent
mplantation and at follow-up. As it states in the Methods section,
Volumes were calculated only if the vascular interface was visualized
very millimeter throughout the stent” (i.e., we did not extrapolate the
EM border for images in which it was not visualized). Thus, not all
atients with EEM volume data at stent implantation had EEM
olume data at follow-up, and vice-versa. Table 2 of the study (1)
eports all the volume data at one time point (postimplantation or
ollow-up) and the statistical analysis for change (and Figure 1 of the
eport [1] displaying change over time) used only patients that had taired postimplantation and follow-up EEM volume data. Hence, the
esults of a trend toward positive remodeling in the TAXUS stent are
ndeed accurate and in concordance with other DES studies.
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ashington, DC 20010
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estenosis, Statistics,
nd Reasonable Inferences
e appreciate the accompanying editorial (1) to our recent report
ntitled “Relationship Between Angiographic Late Loss and Tar-
et Lesion Revascularization After Coronary Stent Implantation:
nalysis From the TAXUS-IV Trial” (2) but we wish to clarify
everal apparent misconceptions. Our principal messages are that
n the era of drug-eluting stents (DES), it is not only the mean
alue but also the shape of the distribution curve (variance and
kewedness) that will determine the population target lesion
evascularization (TLR), and that with a homogeneous response
n-stent late losses up to about 0.75 mm may provide acceptable
linical results (2). That DES may have rightward skewed late loss
istograms has been previously reported (3). The fact that the
ndividual patient late loss/TLR relationship is curvilinear with an
pparent inflection point, rather than linear, had not been reported
nd is a novel and unique observation that has since been replicated
n several other DES trials (DELIVER, ENDEAVOR-II). Most
mportantly, given the rightward skew in patient population data
een in all these trials (including the pivotal SIRIUS trial of the
irolimus-eluting stent), a certain lower level or “floor” of TLR
ay be unavoidable, somewhat independent of the mean late loss.
Moreover, recent data reported at the most recent American
ollege of Cardiology meetings substantiate our findings. The
NDEAVOR-II trial, with a considerably higher mean late loss
0.62 mm) but with rather a homogeneous effect (standard
eviation of late loss 0.46), reported a low TLR of 4.6% with the
BT-578-eluting stent. The large-scale REALITY trial, compar-
ng the sirolimus-eluting and paclitaxel-eluting stents, found
ignificantly greater in-stent late loss with the latter (0.09 vs. 0.31
m, respectively, p  0.001), but nearly identical eight-month
LR rates (5.0% vs. 5.4%, p  0.81). Thus, given the patient and
esion complexity studied in the pivotal DES trials to date, an
acceptable” TLR can be achieved with a relatively high in-stent
ate loss, providing that a homogeneous response is seen.
In addition, other variables beyond angiographic late loss that
ay affect TLR rates must be considered, including the inaccura-
ies and variability of quantitative measures of late loss. Variable
hresholds of patient angina perception, follow-up ischemia detec-
